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INTRODUCTION
In the past few years, a human nasal epithelial cell line derived from septum carcinoma (RPMI 
2650) has been proposed as a potential in vitro model for screening nasally delivered drugs [1-
3]. However, these studies have left some unanswered questions in terms of the validation of the 
in vitro model.
In particular, no clear agreement was found with respect to several parameters, such as 
the seeding density, the time for switching cell culture from Liquid Covered Culture (LCC) to air 
liquid interface (ALI) conditions, or the day at which cell cultures have to be used for transport 
experiments, when these cells are cultured in vitro.
Hence, the aim of this study was to expand on the previous in vitro cell models to better 
define the fundamental parameters to be used as a tool for studying drug deposition and transport 
through the nasal mucosa.
METHODS
RPMI 2650, human nasal septum carcinoma derived cells (ATCC, USA) were grown in 75 cm2 
flasks in complete Minimum Essential Medium (Life Technologies, Australia) containing 10% 
(v/v) fetal bovine serum, 1% (v/v) non-essential amino acid solution and 2 mM L-glutamine, 
which was incubated in a humidified atmosphere of 95% air/5% CO2 at 37°C. 
Cells were seeded on Snapwell™ polyester membrane (1.13 cm2, 0.4 μm pore size, 
Corning Costar, USA; coated with 200 μL of 1 μg/mL collagen solution in PBS 24 hours before 
seeding) at three different seeding densities: 2.5x105, 5.0x105, and 1.0x106 cells/well. After 24 
hours, the medium in the apical chamber was removed to switch cells form the LCC to ALI 
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configuration, in order to develop a differentiated cell layer for further deposition and transport 
studies. The cells were cultured for 21 days and were characterized for mucus production and tight 
junction functionality through trans-epithelial electrical resistance (TEER) and permeability of 
fluorescein sodium (flu-Na).
TEER measurements were recorded every two to three days with an EVOM2 Epithelial 
Voltohmeter (WPI, USA) to evaluate the monolayer integrity and suitability for transport studies 
of the RPMI 2650 cell layers. 
Concurrently, permeability studies using flu-Na, a marker of paracellular transport, were 
performed to evaluate barrier formation and tight junction functionality. Briefly, 250 μL of 2.5 mg/mL 
flu-Na solution were added on the apical chamber and 200 μL samples were taken from the bas-
al chamber at pre-determined time points. Fresh buffer was added to maintain sink conditions. 
In addition, the Snapwells were stained according to a previously described method [4] at specific 
time points to assess the ability of RPMI 2650 for mucus production. Cells were fixed using 4% w/v 
paraformaldehyde, stained using Alcian blue (1% w/v in acetic acid, 3% v/v pH 2.5) and air-dried. 
Alcian blue stains mucus glycoproteins allowing the visualization of mucus production when cells 
are cultured in the ALI configuration. The intensity of the blue color is related with the amount of 
mucus. Images were taken using an Olympus BX60 microscope equipped with an Olympus DP71 
camera.
RESULTS AND DISCUSSION
Culturing conditions to switch from LCC to ALI were evaluated at four different times (1, 2, 4, 
and 8 days after seeding, respectively). Results showed that RPMI 2650 could be changed from the 
LCC to the ALI configuration just after 24 hours, since no significant benefits on cell growth was 
observed from prolonged culture in liquid covered conditions (data not shown). 
In order to evaluate the progressive formation of a viable monolayer over time, TEER 
measurements were performed. Figure 1 shows the profile of TEER values, for each seeding density 
at different days. TEER values increased steadily from day 1 and reached a plateau at day 15 around 
90-100 Ω cm2. These values are similar to TEER previously reported for the same cell line and 
considered suitable for drug permeation experiments [1, 2]. TEER values slightly decreased at day 
21, suggesting a loss of cell viability.
Figure 1. TEER values (Ω cm2) of RPMI2650 grown on Snapwell at different seeding densities (n = 3, ± StDev).
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Permeability studies of the paracellular marker flu-Na were conducted at 1, 2, and 3 weeks 
after seeding. Figure 2 shows the apparent permeability (Papp) calculated for all the three seeding 
densities. A significant decrease of the flu-Na permeability values was observed after the first week. 
The Papp reached a minimum value and was maintained after two and three weeks of culture, with 
values nearly halved in comparison to week one. The Papp at week two and three were not signifi-
cantly different (p > 0.05), suggesting that the monolayer formed tight junctions and differentiated 
after twoweeks of culture in the ALI configuration. Furthermore, permeability values found in 
our model were in close agreement with value reported in literature for human nasal mucosa 
(3.12 ± 1.99 x10-6 cm/s) [4], at two and three weeks in culture.
Figure 2. Values of Flu-Na apparent permeability (10-6 cm/s) on RPMI 2650 cells grown under air-liquid 
interface as function of weeks in culture (n = 3, ± StDev).
Since this in vitro cell model should be representative of the physiological nasal mucosa, 
RPMI 2650 grown under ALI were analyzed to assess their ability to secrete mucus, an important 
aspect not previously investigated. Figure 3 shows the development of a mucus layer on the surface 
of RPMI 2650 cells during the first two weeks for the intermediate seeding density.
Figure 3.  Microscopic images of mucus stained with Alcian blue (dark gray) on the surface of RPMI 2650 nasal 
cells seeded on Snapwell at 5 x105 cells/well and cultured in ALI configuration at day 1, 7, and 14. 
Only slight differences in mucus production were observed for the three different seeding 
densities. Qualitative observation of the images suggested that all cells seeding presented a homo-
geneous mucus layer from the second week of culture onwards.
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 CONCLUSIONS
This study has shown that RPMI 2650 human nasal carcinoma cells grown on Snapwells represent 
a promising in vitro model for nasal drug delivery studies. These cells grown in air-liquid interface 
configuration form monolayers with viable tight junctions and secrete a homogeneous layer of mucus 
after two weeks in culture. For the range evaluated, seeding densities appear to have a limited 
impact on these properties. Further studies, i.e., drug permeation and expression of transporter 
proteins, are required to complete the validation of this in vitro model before it can be used as a 
screening tool for nasally delivered formulations.
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